Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center.
Ann-Lorie GagnonWilliam BeauchesneLaurence TessierCharles DavidDjamal BerbicheAlexandre LavoieAlban Michaud-HerbstKarine TremblayPublished in: Crohn's & colitis 360 (2021)
This study presents long-term treatment persistence data with adalimumab, infliximab, and vedolizumab, showing that more than half of cases treated with these biologics remained on treatment at least 24 months after initiation.